Nutra Pharma Corp.
Bringing Healthcare Solutions to the World
 
Newsroom
Recent News
Archives
E-Alerts
Press Kit
Drug Development
R&D Pipeline
Nutra Pharma is developing an innovative pipeline of biopharmaceutical products
E-Alerts
Signup to receive news and announcements from Nutra Pharma:
First Name:
Last Name:
Email:
Infinite Menus, Copyright 2006, OpenCube Inc. All Rights Reserved.

Newsroom

Nutra Pharma to Present and Exhibit at Upcoming Investment Conferences in Vancouver, Canada, and Las Vegas, Nevada
March 25, 2010

Nutra Pharma has announced that it will be presenting and exhibiting at the upcoming World MoneyShow in Vancouver, Canada, and at the Accredited Members Spring 2010 Small Cap/Micro Cap Investment Conference in Las Vegas, Nevada.

Nutra Pharma Corp., a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS), has announced today that it will be presenting and exhibiting at the upcoming World MoneyShow in Vancouver, Canada, and at the Accredited Members, Inc. Spring 2010 Small Cap/Micro Cap Investment Conference in Las Vegas, Nevada.

“Both the World MoneyShow and the Accredited Members Investment Conference have historically proven to provide excellent venues for building awareness about Nutra Pharma, our drug research, and our recently launched pain relievers, Cobroxin and Nyloxin,” explained Rik J Deitsch, Chairman and CEO of Nutra Pharma Corporation. “As we move through 2010, we plan to continue our outreach efforts and expand our presence within the investment community,” he concluded.

The World MoneyShow, which is scheduled for April 6th through April 8th, will be held at the Hyatt Regency in Vancouver, Canada. The Accredited Members, Inc. Spring 2010 Small Cap/Micro Cap Investment Conference, which is scheduled for April 20th through April 22nd, will be held at the Green Valley Ranch Resort in Las Vegas, Nevada.

SEC Disclaimer

This press release contains forward-looking statements. The words or phrases "would be," "will allow," "intends to," "will likely result," "are expected to," "will continue," "is anticipated," "estimate," "project," or similar expressions are intended to identify "forward-looking statements." Actual results could differ materially from those projected in Nutra Pharma's ("the Company") business plan. The Company's business is subject to various risks, which are discussed in the Company's filings with the Securities and Exchange Commission ("SEC").  The above statements pertaining to the World MoneyShow in Vancouver, Canada, and Accredited Members Investment Conference in Las Vegas, Nevada, should not be construed as an indication in any way whatsoever of: (a) the Company’s financial value; and/or (b) any predictive value of the Company’s future stock price.   The Company's filings may be accessed at the SEC's Edgar system at www.sec.gov.  Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company cautions readers not to place reliance on such statements. Unless otherwise required by applicable law, we do not undertake, and we specifically disclaim any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.


 
Quick Nav
Nyloxin // Chronic Pain Relief
Read about Jeff Gottfurcht, the first rheumatoid arthritis sufferer to conquer Everest, in Musculoskeletal Health a special section of the Washington Post.
 

 

 
Recent News
 
June 21, 2017
Nutra Pharma Announcing Launch of Luxury Feet


June 07, 2017
Nutra Pharma Featured on Univision's Spanish-Language News Show: Primer Impacto


May 31, 2017
Nutra Pharma Announces Collaboration with the University of Maryland Bioprocess Scale-Up Facility in Preparation of Material for Phase II Studies


 
 
Announcements
Click here to view a Letter to Shareholders from the Company's CEO, Rik J Deitsch.
 
 
Facebook   Twitter
 
NPC
Privacy Policy Code of Ethics